Literature DB >> 11568790

A randomized trial that compared oral cefixime and intramuscular ceftriaxone for the treatment of gonorrhea in pregnancy.

R M Ramus1, J S Sheffield, J A Mayfield, G D Wendel.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate prospectively the Centers for Disease Control recommendations for the treatment of gonococcal infection in pregnancy. STUDY
DESIGN: One hundred sixty-one women who were referred with probable endocervical gonorrhea underwent pretreatment endocervical, anal, and oral cultures for Neisseria gonorrhoeae. The women were randomly assigned to receive ceftriaxone 125 mg intramuscularly or cefixime 400 mg orally. Treatment was open and in a 1:1 distribution. There were 95 evaluable patients. The tests of cure cultures were performed 4 to 10 days after treatment.
RESULTS: Eighty-six women (91%) had endocervical infection; 39 women (41%) had anal infection, and 11 women (12%) had pharyngeal infection. Fifty of 95 women (53%) had concomitant endocervical chlamydial infection. The overall efficacy was 91 of 95 subjects (95.8%; 95% CI, 89.6%-98.8%). Ceftriaxone was effective in 41 of 43 cases (95%; 95% CI, 84.2%-99.4%), and cefixime was effective in 50 of 52 cases (96%; 95% CI, 86.8%-99.5%). No significant difference was noted in the overall efficacy or by site of infection. Three of the 4 women who experienced treatment failures admitted to unprotected intercourse before their test of cure culture.
CONCLUSION: Both intramuscular ceftriaxone 125 mg and oral cefixime 400 mg appear to be effective for the treatment of gonococcal infection in pregnancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568790     DOI: 10.1067/mob.2001.117662

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

1.  Management of gonococcal infection among adults and youth: New key recommendations.

Authors:  Lisa Pogany; Barbara Romanowski; Joan Robinson; Margaret Gale-Rowe; Cathy Latham-Carmanico; Christine Weir; Tom Wong
Journal:  Can Fam Physician       Date:  2015-10       Impact factor: 3.275

2.  Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae and repeat infection among pregnant urban adolescents.

Authors:  Erica K Berggren; Loral Patchen
Journal:  Sex Transm Dis       Date:  2011-03       Impact factor: 2.830

Review 3.  Gonorrhoea.

Authors:  Sarah Creighton
Journal:  BMJ Clin Evid       Date:  2011-03-14

Review 4.  Gonorrhoea.

Authors:  Sarah Creighton
Journal:  BMJ Clin Evid       Date:  2014-02-21

Review 5.  Gonorrhoea.

Authors:  John S Moran
Journal:  BMJ Clin Evid       Date:  2007-03-01

Review 6.  Nonviral sexually transmitted infections in pregnancy: current controversies and new challenges.

Authors:  Andreea Waltmann; Tyler R McKinnish; Joseph A Duncan
Journal:  Curr Opin Infect Dis       Date:  2021-02-01       Impact factor: 4.915

7.  Increasing Trend of Resistance to Penicillin, Tetracycline, and Fluoroquinolone Resistance in Neisseria gonorrhoeae from Pakistan (1992-2009).

Authors:  Kauser Jabeen; Summiya Nizamuddin; Seema Irfan; Erum Khan; Faisal Malik; Afia Zafar
Journal:  J Trop Med       Date:  2011-09-15

Review 8.  Antibiotics for treating gonorrhoea in pregnancy.

Authors:  Gabriella Comunián-Carrasco; Guiomar E Peña-Martí; Arturo J Martí-Carvajal
Journal:  Cochrane Database Syst Rev       Date:  2018-02-21

9.  Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015.

Authors:  Michelle J Cole; Gianfranco Spiteri; Susanne Jacobsson; Neil Woodford; Francesco Tripodo; Andrew J Amato-Gauci; Magnus Unemo
Journal:  BMC Infect Dis       Date:  2017-09-11       Impact factor: 3.090

Review 10.  Systematic review and meta-analysis on efficacy of cefixime for treating gonococcal infections.

Authors:  Syed Bilal Tanvir; Syed Saad Bin Qasim; Ali Shariq; Shariq Najeeb; Altaf H Shah
Journal:  Int J Health Sci (Qassim)       Date:  2018 Sep-Oct
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.